Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab

Canadian Journal of Ophthalmology

Volumn 46, Issue 2, 2011, Pages 182-185

  Almony, Arghavan ^a   Mansouri, Azad ^b   Shah, Gaurav K ^b,c   Blinder, Kevin J ^b,c  

^a UNIVERSITY OF MISSOURI   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BARNES RETINA INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CHOROIDAL NEOVASCULAR MEMBRANE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR HEMORRHAGE; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; DRUG ANTAGONISM; INTRAVITREAL DRUG ADMINISTRATION; PHYSIOLOGY; RETINA MACULA DEGENERATION; RETREATMENT; RETROSPECTIVE STUDY; TREATMENT FAILURE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 80052547257     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i10-095     Document Type: Article

References (8)

1. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49:4523-7.
2. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-44. (Pubitemid 44511558)
3. Fung AE, Lalwani GA, Rosenfeld PJ et al. An optical coherence tomography guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-83.
4. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-31. (Pubitemid 44511557)
5. Avery RL, Pieramici DJ, Ravena MD et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-72.
6. Bashshur ZF, Bazarbachi A, Schakal A et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:1-9. (Pubitemid 43946791)
7. La Cour M. Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis? Acta Ophthalmol Scand. 2007;85:2-4.
8. Steinbrook R. The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration. N Eng J Med. 2006;355:1409-12. (Pubitemid 44511554)